NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 2,505.00
-325.00 (-11.48%)
May 18, 2026, 7:45 AM KST
NeoImmuneTech Revenue
In the year 2025, NeoImmuneTech had annual revenue of 94.82M KRW, down -44.35%. NeoImmuneTech had revenue of 38.78M in the quarter ending December 31, 2025, with 1.40% growth.
Revenue
94.82M
Revenue Growth
-44.35%
P/S Ratio
2,611.82
Revenue / Employee
1.82M
Employees
n/a
Market Cap
247.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.82M | -75.56M | -44.35% |
| Dec 31, 2024 | 170.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 476.94B |
| Bioneer | 330.11B |
| Macrogen | 195.27B |
| BINEX | 168.47B |
| GC Cell | 165.52B |
| JETEMA, | 76.90B |
| HLB Therapeutics | 69.56B |
| Anterogen.Co.,Ltd. | 7.54B |